News
Current position:Product center > Cell lines > Immune checkpoints > 4-1BB
4-1BB
Background

     

4-1BB, also known as CD137 or TNFRSF9, is an inducible co-stimulatory receptor belonging to the tumor necrosis factor receptor superfamily. It is expressed in T cells, natural killer (NK) cells, and cells of the innate immune system. The interaction between 4-1BB and its ligand (4-1BBL) promotes cell proliferation, survival, and cytokine production. Current drug development targeting 4-1BB is mainly for treating inflammation, autoimmune diseases, and cancer. Agonistic antibodies targeting 4-1BB have shown promising progress in treating inflammation and autoimmune diseases, while combination therapy targeting 4-1BB along with immune checkpoints or co-stimulatory targets holds potential for enhanced anti-tumor effects.


Drug development targeting 4-1BB can be broadly categorized into two groups: those for treating inflammation or autoimmune diseases, and those for cancer treatment. Unlike traditional targeted therapies for inflammation or autoimmune diseases, most drugs developed for treating these conditions involving 4-1BB are agonistic antibodies rather than inhibitory ones. This difference could be attributed to their potential to induce excessive activation of natural or induced Treg cells, or IFNγ-induced regulatory capabilities in CD8+ T cells. Progress in developing agonistic targeted drugs based on this principle is promising but requires caution.


However, the progress of 4-1BB mAbs in cancer treatment has been less satisfactory. The initial agonistic therapeutic antibodies targeting 4-1BB, such as Pfizer's Utomilumab and BMS's Urelumab, have shown either low efficacy or significant hepatotoxicity. Currently, both are being developed in combination therapy with other drugs.

4-1BB-2.png

Products
Get A Quote
4-1BB Reporter Cell Line
4-1BB Expression Cell Line
Cat. No. Product Stock
GM-C04832
H_TNFRSF9(4-1BB) Reporter 293 Cell line
In-stock
GM-C09468
H_TNFRSF9(4-1BB) Reporter Jurkat Cell line
In-stock
Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Current position:Product Center > Cell lines > Immune checkpoints > 4-1BB
classify
4-1BB
Background

     

4-1BB, also known as CD137 or TNFRSF9, is an inducible co-stimulatory receptor belonging to the tumor necrosis factor receptor superfamily. It is expressed in T cells, natural killer (NK) cells, and cells of the innate immune system. The interaction between 4-1BB and its ligand (4-1BBL) promotes cell proliferation, survival, and cytokine production. Current drug development targeting 4-1BB is mainly for treating inflammation, autoimmune diseases, and cancer. Agonistic antibodies targeting 4-1BB have shown promising progress in treating inflammation and autoimmune diseases, while combination therapy targeting 4-1BB along with immune checkpoints or co-stimulatory targets holds potential for enhanced anti-tumor effects.


Drug development targeting 4-1BB can be broadly categorized into two groups: those for treating inflammation or autoimmune diseases, and those for cancer treatment. Unlike traditional targeted therapies for inflammation or autoimmune diseases, most drugs developed for treating these conditions involving 4-1BB are agonistic antibodies rather than inhibitory ones. This difference could be attributed to their potential to induce excessive activation of natural or induced Treg cells, or IFNγ-induced regulatory capabilities in CD8+ T cells. Progress in developing agonistic targeted drugs based on this principle is promising but requires caution.


However, the progress of 4-1BB mAbs in cancer treatment has been less satisfactory. The initial agonistic therapeutic antibodies targeting 4-1BB, such as Pfizer's Utomilumab and BMS's Urelumab, have shown either low efficacy or significant hepatotoxicity. Currently, both are being developed in combination therapy with other drugs.

4-1BB-2.png

Product List
Get A Quote
4-1BB Reporter Cell Line
4-1BB Expression Cell Line
Cat. No. Product Stock
GM-C09585
Cynomolgus_TNFRSF9(4-1BB) CHO-K1 Cell Line
In-stock
GM-C09585
Cynomolgus_TNFRSF9(4-1BB) CHO-K1 Cell Line
In-stock
Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit